A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoV.
Identifieur interne : 001C07 ( PubMed/Curation ); précédent : 001C06; suivant : 001C08A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoV.
Auteurs : Guangyu Zhao [République populaire de Chine] ; Lanying Du ; Cuiqing Ma ; Ye Li ; Lin Li ; Vincent Km Poon ; Lili Wang ; Fei Yu ; Bo-Jian Zheng ; Shibo Jiang ; Yusen ZhouSource :
- Virology journal [ 1743-422X ] ; 2013.
Descripteurs français
- KwdFr :
- Animaux, Anticorps antiviraux (isolement et purification), Anticorps neutralisants (isolement et purification), Antiviraux (isolement et purification), Coloration et marquage (), Coronavirus (), Coronavirus (immunologie), Glycoprotéine de spicule des coronavirus (génétique), Glycoprotéine de spicule des coronavirus (métabolisme), Humains, Lignée cellulaire, Luciferases (analyse), Luciferases (génétique), Souris, Tests de neutralisation (), VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (génétique), Évaluation préclinique de médicament ().
- MESH :
- analyse : Luciferases.
- génétique : Glycoprotéine de spicule des coronavirus, Luciferases, VIH-1 (Virus de l'Immunodéficience Humaine de type 1).
- immunologie : Coronavirus.
- isolement et purification : Anticorps antiviraux, Anticorps neutralisants, Antiviraux.
- métabolisme : Glycoprotéine de spicule des coronavirus.
- Animaux, Coloration et marquage, Coronavirus, Humains, Lignée cellulaire, Souris, Tests de neutralisation, Évaluation préclinique de médicament.
English descriptors
- KwdEn :
- Animals, Antibodies, Neutralizing (isolation & purification), Antibodies, Viral (isolation & purification), Antiviral Agents (isolation & purification), Cell Line, Coronavirus (drug effects), Coronavirus (immunology), Drug Evaluation, Preclinical (methods), HIV-1 (genetics), Humans, Luciferases (analysis), Luciferases (genetics), Mice, Neutralization Tests (methods), Spike Glycoprotein, Coronavirus (genetics), Spike Glycoprotein, Coronavirus (metabolism), Staining and Labeling (methods).
- MESH :
- chemical , analysis : Luciferases.
- chemical , genetics : Luciferases, Spike Glycoprotein, Coronavirus.
- chemical , isolation & purification : Antibodies, Neutralizing, Antibodies, Viral, Antiviral Agents.
- drug effects : Coronavirus.
- genetics : HIV-1.
- immunology : Coronavirus.
- chemical , metabolism : Spike Glycoprotein, Coronavirus.
- methods : Drug Evaluation, Preclinical, Neutralization Tests, Staining and Labeling.
- Animals, Cell Line, Humans, Mice.
Abstract
Evidence points to the emergence of a novel human coronavirus, Middle East respiratory syndrome coronavirus (MERS-CoV), which causes a severe acute respiratory syndrome (SARS)-like disease. In response, the development of effective vaccines and therapeutics remains a clinical priority. To accomplish this, it is necessary to evaluate neutralizing antibodies and screen for MERS-CoV entry inhibitors.
DOI: 10.1186/1743-422X-10-266
PubMed: 23978242
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001C07
Links to Exploration step
pubmed:23978242Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoV.</title><author><name sortKey="Zhao, Guangyu" sort="Zhao, Guangyu" uniqKey="Zhao G" first="Guangyu" last="Zhao">Guangyu Zhao</name><affiliation wicri:level="1"><nlm:affiliation>State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing</wicri:regionArea></affiliation></author><author><name sortKey="Du, Lanying" sort="Du, Lanying" uniqKey="Du L" first="Lanying" last="Du">Lanying Du</name></author><author><name sortKey="Ma, Cuiqing" sort="Ma, Cuiqing" uniqKey="Ma C" first="Cuiqing" last="Ma">Cuiqing Ma</name></author><author><name sortKey="Li, Ye" sort="Li, Ye" uniqKey="Li Y" first="Ye" last="Li">Ye Li</name></author><author><name sortKey="Li, Lin" sort="Li, Lin" uniqKey="Li L" first="Lin" last="Li">Lin Li</name></author><author><name sortKey="Poon, Vincent Km" sort="Poon, Vincent Km" uniqKey="Poon V" first="Vincent Km" last="Poon">Vincent Km Poon</name></author><author><name sortKey="Wang, Lili" sort="Wang, Lili" uniqKey="Wang L" first="Lili" last="Wang">Lili Wang</name></author><author><name sortKey="Yu, Fei" sort="Yu, Fei" uniqKey="Yu F" first="Fei" last="Yu">Fei Yu</name></author><author><name sortKey="Zheng, Bo Jian" sort="Zheng, Bo Jian" uniqKey="Zheng B" first="Bo-Jian" last="Zheng">Bo-Jian Zheng</name></author><author><name sortKey="Jiang, Shibo" sort="Jiang, Shibo" uniqKey="Jiang S" first="Shibo" last="Jiang">Shibo Jiang</name></author><author><name sortKey="Zhou, Yusen" sort="Zhou, Yusen" uniqKey="Zhou Y" first="Yusen" last="Zhou">Yusen Zhou</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="RBID">pubmed:23978242</idno><idno type="pmid">23978242</idno><idno type="doi">10.1186/1743-422X-10-266</idno><idno type="wicri:Area/PubMed/Corpus">001C07</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001C07</idno><idno type="wicri:Area/PubMed/Curation">001C07</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001C07</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoV.</title><author><name sortKey="Zhao, Guangyu" sort="Zhao, Guangyu" uniqKey="Zhao G" first="Guangyu" last="Zhao">Guangyu Zhao</name><affiliation wicri:level="1"><nlm:affiliation>State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing</wicri:regionArea></affiliation></author><author><name sortKey="Du, Lanying" sort="Du, Lanying" uniqKey="Du L" first="Lanying" last="Du">Lanying Du</name></author><author><name sortKey="Ma, Cuiqing" sort="Ma, Cuiqing" uniqKey="Ma C" first="Cuiqing" last="Ma">Cuiqing Ma</name></author><author><name sortKey="Li, Ye" sort="Li, Ye" uniqKey="Li Y" first="Ye" last="Li">Ye Li</name></author><author><name sortKey="Li, Lin" sort="Li, Lin" uniqKey="Li L" first="Lin" last="Li">Lin Li</name></author><author><name sortKey="Poon, Vincent Km" sort="Poon, Vincent Km" uniqKey="Poon V" first="Vincent Km" last="Poon">Vincent Km Poon</name></author><author><name sortKey="Wang, Lili" sort="Wang, Lili" uniqKey="Wang L" first="Lili" last="Wang">Lili Wang</name></author><author><name sortKey="Yu, Fei" sort="Yu, Fei" uniqKey="Yu F" first="Fei" last="Yu">Fei Yu</name></author><author><name sortKey="Zheng, Bo Jian" sort="Zheng, Bo Jian" uniqKey="Zheng B" first="Bo-Jian" last="Zheng">Bo-Jian Zheng</name></author><author><name sortKey="Jiang, Shibo" sort="Jiang, Shibo" uniqKey="Jiang S" first="Shibo" last="Jiang">Shibo Jiang</name></author><author><name sortKey="Zhou, Yusen" sort="Zhou, Yusen" uniqKey="Zhou Y" first="Yusen" last="Zhou">Yusen Zhou</name></author></analytic><series><title level="j">Virology journal</title><idno type="eISSN">1743-422X</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antibodies, Neutralizing (isolation & purification)</term><term>Antibodies, Viral (isolation & purification)</term><term>Antiviral Agents (isolation & purification)</term><term>Cell Line</term><term>Coronavirus (drug effects)</term><term>Coronavirus (immunology)</term><term>Drug Evaluation, Preclinical (methods)</term><term>HIV-1 (genetics)</term><term>Humans</term><term>Luciferases (analysis)</term><term>Luciferases (genetics)</term><term>Mice</term><term>Neutralization Tests (methods)</term><term>Spike Glycoprotein, Coronavirus (genetics)</term><term>Spike Glycoprotein, Coronavirus (metabolism)</term><term>Staining and Labeling (methods)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Anticorps antiviraux (isolement et purification)</term><term>Anticorps neutralisants (isolement et purification)</term><term>Antiviraux (isolement et purification)</term><term>Coloration et marquage ()</term><term>Coronavirus ()</term><term>Coronavirus (immunologie)</term><term>Glycoprotéine de spicule des coronavirus (génétique)</term><term>Glycoprotéine de spicule des coronavirus (métabolisme)</term><term>Humains</term><term>Lignée cellulaire</term><term>Luciferases (analyse)</term><term>Luciferases (génétique)</term><term>Souris</term><term>Tests de neutralisation ()</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (génétique)</term><term>Évaluation préclinique de médicament ()</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Luciferases</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Luciferases</term><term>Spike Glycoprotein, Coronavirus</term></keywords><keywords scheme="MESH" type="chemical" qualifier="isolation & purification" xml:lang="en"><term>Antibodies, Neutralizing</term><term>Antibodies, Viral</term><term>Antiviral Agents</term></keywords><keywords scheme="MESH" qualifier="analyse" xml:lang="fr"><term>Luciferases</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Coronavirus</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>HIV-1</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Glycoprotéine de spicule des coronavirus</term><term>Luciferases</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Coronavirus</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Coronavirus</term></keywords><keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Anticorps antiviraux</term><term>Anticorps neutralisants</term><term>Antiviraux</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Spike Glycoprotein, Coronavirus</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Drug Evaluation, Preclinical</term><term>Neutralization Tests</term><term>Staining and Labeling</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Glycoprotéine de spicule des coronavirus</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Cell Line</term><term>Humans</term><term>Mice</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Coloration et marquage</term><term>Coronavirus</term><term>Humains</term><term>Lignée cellulaire</term><term>Souris</term><term>Tests de neutralisation</term><term>Évaluation préclinique de médicament</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Evidence points to the emergence of a novel human coronavirus, Middle East respiratory syndrome coronavirus (MERS-CoV), which causes a severe acute respiratory syndrome (SARS)-like disease. In response, the development of effective vaccines and therapeutics remains a clinical priority. To accomplish this, it is necessary to evaluate neutralizing antibodies and screen for MERS-CoV entry inhibitors.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23978242</PMID><DateCompleted><Year>2014</Year><Month>02</Month><Day>24</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1743-422X</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><PubDate><Year>2013</Year><Month>Aug</Month><Day>26</Day></PubDate></JournalIssue><Title>Virology journal</Title><ISOAbbreviation>Virol. J.</ISOAbbreviation></Journal><ArticleTitle>A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoV.</ArticleTitle><Pagination><MedlinePgn>266</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/1743-422X-10-266</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Evidence points to the emergence of a novel human coronavirus, Middle East respiratory syndrome coronavirus (MERS-CoV), which causes a severe acute respiratory syndrome (SARS)-like disease. In response, the development of effective vaccines and therapeutics remains a clinical priority. To accomplish this, it is necessary to evaluate neutralizing antibodies and screen for MERS-CoV entry inhibitors.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this study, we produced a pseudovirus bearing the full-length spike (S) protein of MERS-CoV in the Env-defective, luciferase-expressing HIV-1 backbone. We then established a pseudovirus-based inhibition assay to detect neutralizing antibodies and anti-MERS-CoV entry inhibitors.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Our results demonstrated that the generated MERS-CoV pseudovirus allows for single-cycle infection of a variety of cells expressing dipeptidyl peptidase-4 (DPP4), the confirmed receptor for MERS-CoV. Consistent with the results from a live MERS-CoV-based inhibition assay, the antisera of mice vaccinated with a recombinant protein containing receptor-binding domain (RBD, residues 377-662) of MERS-CoV S fused with Fc of human IgG exhibited neutralizing antibody response against infection of MERS-CoV pseudovirus. Furthermore, one small molecule HIV entry inhibitor targeting gp41 (ADS-J1) and the 3-hydroxyphthalic anhydride-modified human serum albumin (HP-HSA) could significantly inhibit MERS-CoV pseudovirus infection.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Taken together, the established MERS-CoV inhibition assay is a safe and convenient pseudovirus-based alternative to BSL-3 live-virus restrictions and can be used to rapidly screen MERS-CoV entry inhibitors, as well as evaluate vaccine-induced neutralizing antibodies against the highly pathogenic MERS-CoV.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Guangyu</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Du</LastName><ForeName>Lanying</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Cuiqing</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Ye</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Lin</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Poon</LastName><ForeName>Vincent Km</ForeName><Initials>VK</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Lili</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Fei</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Bo-Jian</ForeName><Initials>BJ</Initials></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Shibo</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Yusen</ForeName><Initials>Y</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>08</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Virol J</MedlineTA><NlmUniqueID>101231645</NlmUniqueID><ISSNLinking>1743-422X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.13.12.-</RegistryNumber><NameOfSubstance UI="D008156">Luciferases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="Y">isolation & purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="Y">isolation & purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="Y">isolation & purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017934" MajorTopicYN="N">Coronavirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004353" MajorTopicYN="N">Drug Evaluation, Preclinical</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015497" MajorTopicYN="N">HIV-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008156" MajorTopicYN="N">Luciferases</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013194" MajorTopicYN="N">Staining and Labeling</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>04</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>08</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>8</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>8</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>2</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23978242</ArticleId><ArticleId IdType="pii">1743-422X-10-266</ArticleId><ArticleId IdType="doi">10.1186/1743-422X-10-266</ArticleId><ArticleId IdType="pmc">PMC3765664</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nature. 2003 Nov 27;426(6965):450-4</Citation><ArticleIdList><ArticleId IdType="pubmed">14647384</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Infect Dis. 2013 Feb;17(2):e143-4</Citation><ArticleIdList><ArticleId IdType="pubmed">23270612</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gen Virol. 2004 Oct;85(Pt 10):3109-13</Citation><ArticleIdList><ArticleId IdType="pubmed">15448374</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Chem. 1999 Aug 26;42(17):3203-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10464007</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Nov 2;101(44):15748-53</Citation><ArticleIdList><ArticleId IdType="pubmed">15496474</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Infect Dis. 2005 Mar;11(3):411-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15757556</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gen Virol. 2005 May;86(Pt 5):1435-40</Citation><ArticleIdList><ArticleId IdType="pubmed">15831955</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2007 Mar 30;282(13):9612-20</Citation><ArticleIdList><ArticleId IdType="pubmed">17276993</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2008 Jan 15;180(2):948-56</Citation><ArticleIdList><ArticleId IdType="pubmed">18178835</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2013 Mar 14;495(7440):251-4</Citation><ArticleIdList><ArticleId IdType="pubmed">23486063</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2013 May;87(10):5502-11</Citation><ArticleIdList><ArticleId IdType="pubmed">23468491</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2013 Jun 1;207(11):1743-52</Citation><ArticleIdList><ArticleId IdType="pubmed">23532101</ArticleId></ArticleIdList></Reference><Reference><Citation>Microbes Infect. 2013 Jun;15(6-7):506-10</Citation><ArticleIdList><ArticleId IdType="pubmed">23518265</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2013 Jun 27;368(26):2487-94</Citation><ArticleIdList><ArticleId IdType="pubmed">23718156</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2013 Aug;87(16):9379-83</Citation><ArticleIdList><ArticleId IdType="pubmed">23785207</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2013 Sep;87(17):9939-42</Citation><ArticleIdList><ArticleId IdType="pubmed">23824801</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cell Biochem. 2008 Aug 15;104(6):2335-47</Citation><ArticleIdList><ArticleId IdType="pubmed">18442051</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Microbiol. 2009 Mar;7(3):226-36</Citation><ArticleIdList><ArticleId IdType="pubmed">19198616</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 2009 Jul 10;384(4):486-90</Citation><ArticleIdList><ArticleId IdType="pubmed">19422787</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 2009 Oct 10;393(1):144-50</Citation><ArticleIdList><ArticleId IdType="pubmed">19683779</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 2009 Dec;53(12):4987-98</Citation><ArticleIdList><ArticleId IdType="pubmed">19786602</ArticleId></ArticleIdList></Reference><Reference><Citation>Retrovirology. 2010;7:37</Citation><ArticleIdList><ArticleId IdType="pubmed">20420669</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 2010 Jul 2;397(3):580-5</Citation><ArticleIdList><ArticleId IdType="pubmed">20617558</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2012 Nov 8;367(19):1814-20</Citation><ArticleIdList><ArticleId IdType="pubmed">23075143</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect. 2012 Dec;65(6):477-89</Citation><ArticleIdList><ArticleId IdType="pubmed">23072791</ArticleId></ArticleIdList></Reference><Reference><Citation>MBio. 2012;3(6). pii: e00473-12. doi: 10.1128/mBio.00473-12</Citation><ArticleIdList><ArticleId IdType="pubmed">23170002</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2013;8(1):e53568</Citation><ArticleIdList><ArticleId IdType="pubmed">23320093</ArticleId></ArticleIdList></Reference><Reference><Citation>J Antimicrob Chemother. 2013 Mar;68(3):573-6</Citation><ArticleIdList><ArticleId IdType="pubmed">23221626</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2004 Jun;78(11):5642-50</Citation><ArticleIdList><ArticleId IdType="pubmed">15140961</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001C07 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001C07 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:23978242
|texte= A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoV.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:23978242" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |